Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541518 | 0.89 | KDM4E (0.40) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL17612710 | 0.84 | KDM4E (0.39) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL10079855 | 0.82 | ALDH1A1 (0.41) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL10059426 | 0.82 | MGLL (0.44) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL142233 | 0.82 | NR1H3 (0.38) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL14532059 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL16541517 | 0.82 | IDH1 (0.45) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL23619123 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL147797 | 0.81 | KDM4E (0.55) | ALDH1A1KDM4ECYP1A2HPGDBLM | |
| SCHEMBL3729672 | 0.81 | ALDH1A1 (0.55) | ALDH1A1KDM4ECYP1A2HPGDBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9527816-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9527816-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2591784-B1 | Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system | INTERMUNE INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-9290450-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-8969347-B2 | Compounds and methods for treating inflammatory and fibrotic disorders | INTERMUNE, INC. | 2015-03-03 | — | — | US | disclosed |
| EP-1928454-B1 | PYRIDONE DERIVATIVES FOR MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| WO-2010085805-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | INTERMUNE, INC. | 2010-07-29 | — | — | US | disclosed |
| US-7728013-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728013-B2 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20100029578-A1 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds | INTERMUNE, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029578-A1 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds | INTERMUNE, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2007062167-A9 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007062167-A2 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007053685-A2 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS | INTERMUNE, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190731-A1 | METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS | TNNI3, FABP3, TNNT2 | ALDH1A1 94/4885KDM4E 2408/4885CYP1A2 2127/4885 |
| US-20100029578-A1 | Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds | ATF1, MAPKAPK3, MAPKAPK2 | ALDH1A1 900/4885KDM4E 4212/4885CYP1A2 1526/4885 |
| US-10010536-B2 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | ALDH1A1 3375/4885KDM4E 3655/4885CYP1A2 2848/4885 |
| US-20170095462-A1 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | MAPKAPK2, MAP3K6, MAP4K1 | ALDH1A1 3375/4885KDM4E 3655/4885CYP1A2 2848/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | ALDH1A1 2054/4885KDM4E 3381/4885CYP1A2 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.